Absci Reports Sharp Q1 Revenue Decline and Widened Net Loss; Maintains 12-Month Cash Runway

summarizeSummary

Absci Corp reported a substantial 83% decrease in Q1 2026 partner program revenue and a widened net loss, though its cash and marketable securities provide a runway of at least 12 months, supported by recent ATM share sales.

check_boxKey Events

• Steep Revenue Decline

  Partner program revenue plummeted by 83% to $0.2 million in Q1 2026, down from $1.2 million in Q1 2025, primarily due to the timing and mix of ongoing program activity.

• Increased Net Loss

  The company reported a net loss of $29.6 million for the three months ended March 31, 2026, an increase from a net loss of $26.3 million in the prior-year period.

• Cash Position and Runway

  Absci ended Q1 2026 with $125.7 million in cash, cash equivalents, and marketable securities, which management believes will be sufficient to fund operations for at least the next 12 months.

• ATM Program Utilization

  During Q1 2026, the company issued and sold 2,871,218 shares, generating $8.0 million in net proceeds through its at-the-market (ATM) offering program.

auto_awesomeAnalysis

Absci Corp's Q1 2026 financial results show a significant deterioration in revenue and an increase in net losses, highlighting ongoing operational challenges for the clinical-stage biopharmaceutical company. Partner program revenue plunged by 83% year-over-year, indicating a substantial slowdown in its core business activities. Despite the increased losses, the company's cash position of $125.7 million, bolstered by an $8.0 million capital raise through an at-the-market (ATM) offering, is projected to provide a cash runway of at least 12 months. This suggests that while the company faces headwinds in revenue generation and profitability, its near-term liquidity is managed. Investors should monitor future revenue trends and the progress of its clinical pipeline, particularly the upcoming data readouts for ABS-201, as these will be critical for long-term valuation.